ZAFGEN, INC. Contracts & Agreements

Employment Agreement dated May 23, 2023, by and between the Company and Russell Clayton (Filed With SEC on August 10, 2023)

Underwriting Agreement (Filed With SEC on September 14, 2022)

Second Amendment to License Agreement, by and between the Company and The Trustees of Indiana University, effective as of May 28, 2020 (Filed With SEC on August 11, 2022)

Third Amendment to License Agreement, by and between the Company and The Trustees of Indiana University, effective as of June 9, 2022 (Filed With SEC on August 11, 2022)

Securities Purchase Agreement, dated as of May 21, 2021, by and among Larimar Therapeutics, Inc. and the investors listed on the Schedule of Investors attached thereto (Filed With SEC on May 21, 2021)

Form of Pre-Funded Warrant (Filed With SEC on May 21, 2021)

Form of Registration Rights Agreement, by and among Larimar Therapeutics, Inc. and certain Investors (Filed With SEC on May 21, 2021)

Form of Amended and Restated Registration Rights Agreement, by and among Larimar Therapeutics, Inc. and certain Investors (Filed With SEC on May 21, 2021)

First Amendment to Master Services Agreement, dated as of November 9, 2018, by and between the Company and KBI Biopharma, Inc (Filed With SEC on May 10, 2021)

Master Services Agreement, dated as of September 20, 2017, by and between the Company and KBI Biopharma, Inc (Filed With SEC on May 10, 2021)

Description of the Companys Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 4, 2021)

Sublease, dated October 27, 2020 by and between Larimar Therapeutics, Inc. and Massachusetts Municipal Association, Inc (Filed With SEC on October 30, 2020)

Larimar Therapeutics, Inc. Form of Stock Option Grant Notice and Award Agreement (Filed With SEC on September 29, 2020)

Larimar Therapeutics, Inc. 2020 Equity Incentive Plan (Filed With SEC on September 29, 2020)

Larimar Therapeutics, Inc. Form of Stock Option Grant Notice and Award Agreement (Filed With SEC on September 29, 2020)

Larimar Therapeutics, Inc. 2020 Equity Incentive Plan (Filed With SEC on September 29, 2020)

License Agreement, by and between the Company and Wake Forest University Health Sciences, effective as of November 30, 2016 (Filed With SEC on August 14, 2020)

Amendment 1 to License Agreement, by and between the Company and Wake Forest University Health Sciences, effective as of November 28, 2017 (Filed With SEC on August 14, 2020)

Amendment 2 to License Agreement, by and between the Company and Wake Forest University Health Sciences, effective as of March 29, 2019 (Filed With SEC on August 14, 2020)

License Agreement, by and between the Company and Indian University Research and Technology Corporation, effective as of November 30, 2016 (Filed With SEC on August 14, 2020)

First Amendment to License Agreement, by and between the Company, the Trustee of Indiana University and Indiana University Research and Technology Corporation, effective as of... (Filed With SEC on August 14, 2020)

Employment Agreement by and between the Company and Carole Ben-Maimon, M.D., dated July 31, 2020 (including an attached exhibit entitled Confidentiality, Intellectual Property... (Filed With SEC on August 6, 2020)

Form of Pre-Funded Warrant (Filed With SEC on June 2, 2020)

Employment Agreement, dated June 1, 2020, by and between the Company and Michael Celano (Filed With SEC on June 2, 2020)

Form of Indemnification Agreement between the Company and its directors (Filed With SEC on June 2, 2020)

Registration Rights Agreement, dated as of June 1, 2020 by and among Larimar Therapeutics, Inc. and certain Investors (Filed With SEC on June 2, 2020)

Securities Purchase Agreement, dated as of May 28, 2020 by and among Larimar Therapeutics, Inc. and the investors listed on the Schedule of Investors attached thereto (Filed With SEC on June 2, 2020)

Amendment No. 1 to Agreement and Plan of Merger, dated as of March 6, 2020, by and among Zafgen, Inc., Chondrial Therapeutics, Inc., Chondrial Therapeutics Holdings, LLC, and... (Filed With SEC on March 9, 2020)

Description of Registrants Securities 10.1# Amended and Restated 2006 Stock Option Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.1 of the... (Filed With SEC on March 5, 2020)

First Amendment to Severance and Change-in-Control Agreement by and between Registrant and Priya Singhal dated September 12, 2019 (Filed With SEC on March 5, 2020)

First Amendment to Non-Qualified Stock Option Agreement Inducement Award by and between Registrant and Jeffrey S. Hatfield granted on October 9, 2017 (Filed With SEC on March 5, 2020)

Agreement and Plan of Merger, dated as of December 17, 2019, by and among Zafgen, Inc., Chondrial Therapeutics, Inc., Chondrial Therapeutics Holdings, LLC, and Zordich Merger Sub,... (Filed With SEC on December 18, 2019)

First Amendment to Severance and Change-in-Control Agreement for Jeffrey Hatfield dated September 12, 2019 (Filed With SEC on September 12, 2019)

First Amendment to Severance and Change-in-Control Agreement for Brian McVeigh dated September 12, 2019 (Filed With SEC on September 12, 2019)

First Amendment to Severance and Change-in-Control Agreement for Patricia Allen dated September 12, 2019 (Filed With SEC on September 12, 2019)

Severance and Change in Control Agreement by and between the Registrant and Priya Singhal, M.D., M.P.H., effective as of March 4, 2019 (Filed With SEC on May 9, 2019)

Non-Qualified Stock Option Agreement Inducement Award by and between the Registrant and Priya Singhal, M.D., M.P.H. granted on April 2, 2019 (Filed With SEC on May 9, 2019)

Employment Offer Letter Agreement by and between the Registrant and Priya Singhal, M.D., M.P.H., effective as of March 4, 2019 (Filed With SEC on May 9, 2019)

Commercial Lease by and between the Registrant and Shigo Center Plaza Owner, LLC dated as of February 12, 2019 (Filed With SEC on May 9, 2019)

Sales Agreement dated November 9, 2018 by and between Zafgen, Inc. and Cowen and Company, LLC (Filed With SEC on November 9, 2018)

Non-Qualified Stock Option Agreement Inducement Award by and between Registrant and Brian P. McVeigh granted on May 29, 2018 (Filed With SEC on August 9, 2018)

Underwriting Agreement, dated as of June 27, 2018, among Zafgen, Inc. and Cowen and Company, LLC and Piper Jaffray & Co., as representatives of the underwriters named therein (Filed With SEC on June 28, 2018)

Employment Offer Letter Agreement by and between Zafgen, Inc. and Brian P. McVeigh, effective as of May 29, 2018 (Filed With SEC on May 30, 2018)

Severance and Change in Control Agreement by and between Zafgen, Inc. and Brian P. McVeigh, effective as of May 29, 2018 (Filed With SEC on May 30, 2018)

Waiver to Financing Condition by and between Registrant and Jeffrey S. Hatfield, effective as of December 29, 2017 (Filed With SEC on March 9, 2018)

Non-Qualified Stock Option Agreement Inducement Award by and between Registrant and Jeffrey S. Hatfield granted on October 9, 2017 (Filed With SEC on March 9, 2018)

Loan and Security Agreement dated December 29, 2017 between Zafgen, Inc., as borrower, and Silicon Valley Bank, as lender (Filed With SEC on January 5, 2018)

Severance and Change in Control Agreement by and between Zafgen, Inc. and Jeffrey S. Hatfield, effective as of October 9, 2017 (Filed With SEC on October 12, 2017)

Employment Offer Letter Agreement by and between Zafgen, Inc. and Jeffrey S. Hatfield, effective as of October 9, 2017 (Filed With SEC on October 12, 2017)

Employment Offer Letter Agreement by and between Zafgen, Inc. and Thomas E. Hughes, effective as of October 9, 2017 (Filed With SEC on October 12, 2017)

SEVERANCE AND CHANGE IN CONTROL AGREEMENT (Filed With SEC on August 5, 2016)

LEASE BETWEEN LJ GATEWAY OFFICE LLC AND ZAFGEN, INC. LEASE (Short Form) (Filed With SEC on March 15, 2016)

COMMERCIAL LEASE ARTICLE I (Parties) (Filed With SEC on May 14, 2015)

ZAFGEN, INC. [] Shares of Common Stock, par value $0.001 per share Underwriting Agreement (Filed With SEC on January 16, 2015)

AMENDMENT NO. 4 TO EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on January 12, 2015)

SUBSCRIPTION AGREEMENT (Filed With SEC on January 12, 2015)

ZAFGEN, INC. [] Shares ofCommon Stock, par value $0.001 per share Underwriting Agreement (Filed With SEC on June 5, 2014)

One Broadway, 8th Floor Cambridge, MA 02142 (Filed With SEC on June 5, 2014)

ZAFGEN, INC. 2014 STOCKOPTION AND INCENTIVE PLAN (Filed With SEC on June 5, 2014)

ZAFGEN, INC. 2014EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on June 5, 2014)

COMMERCIAL LEASE ARTICLE I (Parties) (Filed With SEC on June 2, 2014)

ZAFGEN, INC. FORM OFDIRECTOR INDEMNIFICATION AGREEMENT (Filed With SEC on June 2, 2014)

ZAFGEN, INC. FORM OFOFFICER INDEMNIFICATION AGREEMENT (Filed With SEC on June 2, 2014)

ZAFGEN, INC. SENIOREXECUTIVE CASH INCENTIVE BONUS PLAN (Filed With SEC on June 2, 2014)

Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement (Filed With SEC on April 18, 2014)

***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 EXCLUSIVE... (Filed With SEC on April 18, 2014)

Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement (Filed With SEC on April 18, 2014)

One Broadway, 8th Floor Cambridge, MA 02142 (Filed With SEC on April 18, 2014)

Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement (Filed With SEC on April 18, 2014)

33 Newbury Street Boston, MA 02116 (Filed With SEC on April 18, 2014)

ONE BROADWAY CAMBRIDGE.MASSACHUSETTS LEASE SUMMARY SHEET (Filed With SEC on April 18, 2014)

***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 EXCLUSIVE... (Filed With SEC on April 18, 2014)

ZAFGEN, INC. AMENDED AND RESTATED 2006 STOCK OPTIONPLAN (Filed With SEC on April 18, 2014)

THIRD AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT BY AND AMONG ZAFGEN,INC. AND THEINVESTORS NAMED HEREIN November 25, 2013 TABLE OF CONTENTS (Filed With SEC on April 18, 2014)